Forcier R J, McIntyre O R, Nissen N I, Pajak T F, Glidewell O, Holland J F
Med Pediatr Oncol. 1978;4(4):351-62. doi: 10.1002/mpo.2950040412.
A randomized therapeutic trial of three induction regimens for patients with lymphosarcoma and reticulum-cell sarcoma was conducted by the Cancer and Leukemia Group B (CALGB) (formerly Acute Leukemia Group B.) Addition of streptonigrin, but not cyclophosphamide, to the combination of vincristine and prednisone improved the complete remission rate achieved after a 42-day induction program. The duration of the subsequent remission and survival was not influenced by the induction combination assigned. Remission maintenance with cyclophosphamide was superior to maintenance with methotrexate. The results of this study are compared with others in which advantages for three or four drug treatment regimens have been reported.
癌症与白血病B组（CALGB，前身为急性白血病B组）对患有淋巴肉瘤和网状细胞肉瘤的患者进行了三种诱导方案的随机治疗试验。在长春新碱和泼尼松的联合用药中加入链黑菌素（而非环磷酰胺），可提高42天诱导方案后的完全缓解率。后续缓解期和生存期不受所分配诱导联合方案的影响。用环磷酰胺维持缓解优于用甲氨蝶呤维持缓解。本研究结果与其他报道三种或四种药物治疗方案优势的研究结果进行了比较。
